2. Search Result
Search Result
Results for "

tumor immunogenicity

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dyes

7

Peptides

2

Inhibitory Antibodies

2

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W075517
    ZIF-8

    2-Methylimidazole zinc salt

    		 MOFs Caspase Pyroptosis Cancer
    ZIF-8 (2-Methylimidazole zinc salt) is a pyroptosis inducer that activates the caspase-1/gasdermin D-dependent pyroptosis pathway. ZIF-8 induces pyroptotic cell death accompanied by necrosis and immunogenic cell death. ZIF-8 initiates in situ immunity, activates anti-tumor immunity, and reprograms the immunosuppressive tumor microenvironment to inhibit tumor growth. ZIF-8 acts as a pH-responsive and stimulus-responsive drug release inducer. ZIF-8 is applicable to cancer-related research .
    ZIF-8
  • HY-175751
    LRK-4189

    		mTOR Cancer
    LRK-4189 is an orally active PIP4K2C (a regulator of mTOR complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .
    LRK-4189
  • HY-N0819
    Raddeanin A
    1 Publications Verification

    		 Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK Neurological Disease Inflammation/Immunology Cancer
    Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .
    Raddeanin A
  • HY-141831
    STF-1084

    		Phosphodiesterase (PDE) Cancer
    STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity .
    STF-1084
  • HY-163099
    P5(PEG24)-VC-PAB-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Apoptosis Cancer
    P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
    P5(PEG24)-VC-PAB-Exatecan
  • HY-160696
    ORIC-533

    		CD73 Cancer
    ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka=0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with Daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8 + T cell infiltration and inhibits tumor growth in vivo .
    ORIC-533
  • HY-153598
    LD4172

    		PROTACs RIP kinase Apoptosis Inflammation/Immunology Cancer
    LD4172 is a selective RIPK1 PROTAC degrader with a Ki of 4.8 nM. LD4172 induces RIPK1 protein degradation via ternary complex formation with RIPK1 and VHL E3 ligase, driving ubiquitination and proteasomal breakdown. LD4172 abrogates TNF-induced classical NF-κB signaling in TRAF2-deficient cells, impairing IκBα phosphorylation and degradation, and reducing IL-8 production. LD4172 induces apoptosis and immunogenic cell death in tumor cells, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy. LD4172 acts as a chemical probe for investigating RIPK1 scaffolding functions. LD4172 can be used for the research of melanoma, colon cancer .
    LD4172
  • HY-16129
    CBP-501

    		Calmodulin Checkpoint Kinase (Chk) MAPKAPK2 (MK2) MAP3K Cancer
    CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer .
    CBP-501
  • HY-P99687
    Latikafusp

    AMG 256

    		 PD-1/PD-L1 Cancer
    Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
    Latikafusp
  • HY-173178
    LNS8801

    		Estrogen Receptor/ERR Cancer
    LNS8801 is an orally active agonist of the G protein-coupled estrogen receptor (GPER). By activating GPER, LNS8801 mediates downstream signaling pathways, such as promoting the production of cyclic adenosine monophosphate (cAMP) and activating the cAMP response element-binding protein (CREB) signaling, thereby exerting anti-tumor activities including inhibiting tumor cell proliferation, inducing cell differentiation, and enhancing tumor immunogenicity. LNS8801 can be used in the research of various cancers (e.g., melanoma, pancreatic cancer, colorectal cancer, lung cancer, etc.) and relevant studies exploring the roles of GPER in normal physiological and pathological processes .
    LNS8801
  • HY-158189
    TPP-Ce6

    		Photosensitizer Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Cancer
    TPP-Ce6 is a mitochondria-targeted photosensitizer formed by the ester bond conjugation of chlorophyll e6 (Ce6) with triphenylphosphine (TPP). Under light irradiation or ultrasound exposure, TPP-Ce6 generates reactive oxygen species, induces cell apoptosis, and triggers immunogenic cell death. TPP-Ce6 can serve as a component of carrier-free co-delivery systems, undergo enzyme-induced self-assembly within tumors, and modulate tumor hypoxia. TPP-Ce6 is applicable to research on breast cancer and glioblastoma .
    TPP-Ce6
  • HY-162863
    ERK-MYD88 interaction inhibitor 1

    		Apoptosis Cancer
    ERK-MYD88 interaction inhibitor 1 is an ERK-MYD88 interaction inhibitor. ERK-MYD88 interaction inhibitor 1 can induce an HRI-mediated integrated stress response (ISR), leading to cancer cell-specific immunogenic cell apoptosis (apoptosis). ERK-MYD88 interaction inhibitor 1 can induce anti-tumor T cell responses in Lewis lung cancer mice, exhibiting anti-tumor activity .
    ERK-MYD88 interaction inhibitor 1
  • HY-149631
    HFY-4A

    		HDAC Cancer
    HFY-4A is a HDAC inhibitor. HFY-4A inhibits breast cancer cell proliferation, migration, and invasion, and induces cell apoptosis. HFY-4A induces immunogenic cell death (ICD). HFY-4A inhibits tumor growth in breast cancer xenograft mouse models .
    HFY-4A
  • HY-177483
    OART

    Oxaliplatin-artesunate

    		 Ferroptosis Mitochondrial Metabolism Glutathione Peroxidase Transferrin Receptor MMP Dihydroorotate Dehydrogenase Cancer
    OART (Oxaliplatin-artesunate) is a ferroptosis inducer. OART significantly inhibits tumor cell proliferation. OART induces cytoplasmic and mitochondrial LPO to promote tumor ferroptosis, via destroying glutathione-mediated ferroptosis defense system and enhancing iron-dependent Fenton reaction. OART enhances tumor immunogenicity, transforming tumor environment from immunosuppressive to immunosensitive. OART has strong tumor regression in tumor-bearing mouse models. OART can be used for cancer immunotherapy research .
    OART
  • HY-16129A
    CBP-501 acetate

    		Calmodulin MAP3K MAPKAPK2 (MK2) Checkpoint Kinase (Chk) Cancer
    CBP-501 acetate, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 acetate is used for various types of cancer .
    CBP-501 acetate
  • HY-161693
    Telomeric G4s ligand 1

    		G-quadruplex DNA/RNA Synthesis Apoptosis Cancer
    Telomeric G4s ligand 1 is a telomeric G-quadruplex ligand that stabilizes telomeric G4 and induces R-loop formation, leading to DNA damage responses. Telomeric G4s ligand 1 induces apoptosis and evokes immunogenic cell death (ICD) in tumor cells .
    Telomeric G4s ligand 1
  • HY-145414
    DYSP-C34

    		Reactive Oxygen Species (ROS) Cancer
    DYSP-C34 is a potent, biocompatible, and ultrasound (US)-triggered multifunctional molecular machine. DYSP-C34 has multiple favorable properties, such as improved lipophilic/hydrophilic balance, intensified US-induced ROS production capacity, and better cellular permeability, resulting in the excellent tumor target efficiency and notable sonodynamic therapy (SDT)-mediated tumor regression. DYSP-C34 exhibits mild immunogenicity by stimulating APCs directly .
    DYSP-C34
  • HY-169225A
    PDIC-NN dimethanesulfonate

    PDIC-NS

    		 STING Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    PDIC-NN dimethanesulfonate (PDIC-NS) is a STING activator with anticancer activity. PDIC-NN dimethanesulfonate promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN dimethanesulfonate triggers ROS burst and causes serious damage to mitochondria. PDIC-NN dimethanesulfonate induces cell apoptosis and inhibits DNA replication. PDIC-NN dimethanesulfonate activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response .
    PDIC-NN dimethanesulfonate
  • HY-177414
    BB-1701

    		Antibody-Drug Conjugates (ADCs) EGFR Inflammation/Immunology Cancer
    BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .
    BB-1701
  • HY-168492
    TrxR/EGFR-IN-1

    		Ferroptosis EGFR TrxR Apoptosis Cancer
    TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor. TrxR/EGFR-IN-1 is active against both Gefitinib (HY-50895)-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. TrxR/EGFR-IN-1 promotes the degradation of GPX4 protein through autophagolysosomal and proteasomal pathways, leading to ferroptosis. In addition, TrxR/EGFR-IN-1 can induce endoplasmic reticulum stress and trigger immunogenic cell death. TrxR/EGFR-IN-1 can be used for the research of Gefitinib (HY-50895)-resistant lung cancer .
    TrxR/EGFR-IN-1
  • HY-162958
    Photosensitizer-6

    		Apoptosis TrxR Cancer
    Photosensitizer-6 (Compound 4) is a gold (I) complex and exhibits inhibitory activity against TrxR. Photosensitizer-6 induces apoptosis in 4T1 cell, targets and eradicates tumors through chemo-phototherapy and immunogenic cell death under light exposure. Photosensitizer-6 can be used for tumor imaging .
    Photosensitizer-6
  • HY-P10295
    p53 (232-240)

    		MDM-2/p53 Cancer
    p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
    p53 (232-240)
  • HY-170971
    Src Inhibitor 4

    		Apoptosis Src Cancer
    Src Inhibitor 4 (Compound 18) is a derivative of KX-01 and an Src inhibitor. Src Inhibitor 4 can inhibit tumor cells, disrupt microtubules, and induce cell cycle arrest, apoptosis, and immunogenic cell death. After the introduction of phenolic or aniline functionality, Src Inhibitor 4 can serve as a payload attachment site for antibody-drug conjugates and has anti-tumor activity .
    Src Inhibitor 4
  • HY-13735H
    Quinacrine acetate

    Acriquine acetate

    		 Parasite Sodium Channel DNA Stain Apoptosis Cancer
    Quinacrine (Acriquine) acetate is a small molecule modulator of the cGAS-STING-TBK1 signaling pathway, possessing immune stimulatory activity. Quinacrine acetate has been explored for its potential therapeutic applications in enhancing anti-tumor immunity. Quinacrine acetate can improve the effectiveness of cancer immunotherapies by addressing the poor immunogenicity of various tumors. Quinacrine acetate also presents a promising strategy for overcoming the limitations associated with immune checkpoint inhibitors in cancer treatment.
    Quinacrine acetate
  • HY-153545
    9-Amino-NeuAc

    		Liposome Cancer
    9-Amino-NeuAc is a substrate of synthase. 9-Amino-NeuAc can be converted to CMP9-amino-NeuAc, activated to the corresponding CMPglycoside and transferred to asialoglycoprotein. 9-Amino-NeuAc can be used to target liposome synthesis while modulating tumor surface immunogenicity .
    9-Amino-NeuAc
  • HY-169225
    PDIC-NN

    PDIC-NS free base

    		 STING Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    PDIC-NN (PDIC-NS free base) is a STING activator with anticancer activity. PDIC-NN promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN triggers ROS burst and causes serious damage to mitochondria. PDIC-NN induces cell apoptosis and inhibits DNA replication. PDIC-NN activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response .
    PDIC-NN
  • HY-158775
    Ferroptocide

    		Ferroptosis Apoptosis Autophagy Cancer
    Ferroptocide is a cell death inducer that triggers ferroptosis and has anti-tumor activity. Ferroptocide can induce oxidative stress, leading to G2/M cell cycle arrest and apoptosis activation in LNCaP cells, while also effectively inhibiting the cell viability of both LNCaP and TRAMP-C1 cells. Ferroptocide can be used to study its capability to induce mitochondrial autophagy and to trigger immunogenic cell death (ICD) in prostate cancer cells .
    Ferroptocide
  • HY-162264
    Tubulin polymerization/V-ATPase-IN-1

    		Microtubule/Tubulin Proton Pump Apoptosis Inflammation/Immunology Cancer
    Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration .
    Tubulin polymerization/V-ATPase-IN-1
  • HY-173023
    IDOi-Pt(IV) prodrug-1

    		Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species (ROS) Cancer
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .
    IDOi-Pt(IV) prodrug-1
  • HY-N0819R
    Raddeanin A (Standard)

    		Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK Neurological Disease Inflammation/Immunology Cancer
    Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
    Raddeanin A (Standard)
  • HY-183623
    ProAlk01

    		ADC Payload Apoptosis Cancer
    ProAlk01 is a protein alkylating agent that serves as a toxin payload for ADCs. ProAlk01 localizes to the cytoplasm and exerts cytotoxic effects mainly by alkylating cytoplasmic proteins rather than binding to DNA. ProAlk01 induces cell cycle arrest, apoptosis, and immunogenic cell death. ProAlk01 can be used in the research of solid tumors .
    ProAlk01
  • HY-183570
    Antitumor photosensitizer-11

    		Photosensitizer Reactive Oxygen Species (ROS) Cancer
    Antitumor photosensitizer-11 is a type-I carbazole/benzindolium photosensitizer with antitumor activity. Antitumor photosensitizer-11 induces ROS generation via a type-I pathway, forming superoxide anions and hydroxyl radicals. Antitumor photosensitizer-11 triggers immunogenic cell death in cancer cells via enhanced oxidative stress. Antitumor photosensitizer-11 exhibits antiproliferative activity in normoxic and hypoxic environments, inhibits breast cancer tumor growth in vivo, and promotes dendritic cell maturation and T cell infiltration. Antitumor photosensitizer-11 can be used for the research of cancer, such as breast cancer .
    Antitumor photosensitizer-11
  • HY-181673
    ICD inducer-2

    		Microtubule/Tubulin Apoptosis Bcl-2 Family Caspase PARP Cancer
    ICD inducer-2 is a immunogenic cell death inducer. ICD inducer-2 binds to the colchicine binding site on tubulin to inhibit tubulin polymerization. ICD inducer-2 exhibits broad-spectrum antiproliferative activity across multiple cancer cell lines. ICD inducer-2 inhibits cells migration, causes G2/M phase and induces apoptosis. ICD inducer-2 promotes infiltration of CD4+ and CD8+ T cells into the tumor microenvironment. ICD inducer-2 downregulates antiapoptotic protein Bcl-2, upregulates proapoptotic proteins Bax and Bim-1, and increases cleaved caspase 3, cleaved caspase 9, and cleaved PARP levels. ICD inducer-2 overcomes paclitaxel resistance in xenograft models and achieves tumor growth inhibition. ICD inducer-2 can be used for the research of cancer, such as lung carcinoma .
    ICD inducer-2
  • HY-P992473
    TAS266

    		TNF Receptor Inflammation/Immunology Cancer
    TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors .
    TAS266
  • HY-181718
    Necroptosis inducer 1

    		Necroptosis TrxR Reactive Oxygen Species (ROS) Cancer
    Necroptosis inducer 1 is a necroptosis inducer. Necroptosis inducer 1 inhibits the activity of thioredoxin reductase (TrxR), elevates intracellular ROS levels, triggers ROS-mediated necroptosis, and induces necroptosis-dependent immunogenic cell death. Necroptosis inducer 1 inhibits tumor growth, remodels the tumor immune microenvironment, and exerts a synergistic effect with anti-PD-1 in animal models. Necroptosis inducer 1 is applicable to the research of colon cancer .
    Necroptosis inducer 1
  • HY-181017
    Ola-NC-SS-PEG-Lap

    		Reactive Oxygen Species (ROS) DNA/RNA Synthesis PARP Quinone Reductase Cancer
    Ola-NC-SS-PEG-Lap is a selective immunogenic cell death inducer. Ola-NC-SS-PEG-Lap exploits the synergistic interplay between an NQO1-bioactivated compound and a PARP inhibitor to selectively induce immunogenic cell death in tumor cells without harming normal cells. Ola-NC-SS-PEG-Lap induces ROS accumulation, increases DNA damage. Ola-NC-SS-PEG-Lap can be activated by GSH and release Ola, ultimately producing the synergistic antitumor effect with the Lap portion. Ola-NC-SS-PEG-Lap has anti-cancer activity against colon cancer .
    Ola-NC-SS-PEG-Lap
  • HY-106187B
    MART-1 (27-35) (human) TFA

    		Cancer
    MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma .
    MART-1 (27-35) (human) TFA
  • HY-183554
    Fa-Au

    		TrxR Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS) IFNAR STAT Cancer
    Fa-Au is a TrxR inhibitor. Fa-Au downregulates GPX4, induces oxidative stress, mitochondria-associated ferroptosis (ferroptosis) and immunogenic cell death. Fa-Au induces ROS production in hepatoma cells. Fa-Au remodels the tumor immune microenvironment via M1 macrophage polarization, dendritic cell maturation, CD8+ T cell activation and reduction of regulatory T cells. Fa-Au induces an anti-tumor immune feedback loop through the IFNγ/STAT1/SLC7A11 axis. Fa-Au inhibits tumor growth. Fa-Au is applicable to hepatocellular carcinoma-related research .
    Fa-Au
  • HY-181599
    XAN-5

    		Mitochondrial Metabolism DNA/RNA Synthesis Reactive Oxygen Species (ROS) Apoptosis Autophagy Caspase Bcl-2 Family Atg8/LC3 Cancer
    XAN-5 is a mitochondrial DNA G-quadruplex (mtG4) ligand with a Kd of 3.8 μM. XAN-5 selectively binds and stabilizes mtG4 structures, disrupting mitochondrial gene transcription and DNA replication. XAN-5 triggers mitochondrial dysfunction, ROS overproduction, G0 phase arrest and caspase-dependent apoptosis. XAN-5 inhibits autophagy and induces immunogenic cell death. XAN-5 inhibits tumor growth in a mouse liver cancer model while enhancing tumor-infiltrating CD4 + and CD8 + T cells. XAN-5 targets two cancer resistance mechanisms simultaneously. XAN-5 can be used for the research of liver cancer .
    XAN-5
  • HY-180245
    STAT3-IN-51

    		STAT Ferroptosis Apoptosis Glutathione Peroxidase Bcl-2 Family Reactive Oxygen Species (ROS) Cancer
    STAT3-IN-51 is a STAT3 inhibitor that directly binds to the STAT3 SH2 domain. STAT3-IN-51 induces apoptosis, ferroptosis, and immunogenic cell death (ICD) to potentiate anti-tumor immunity. STAT3-IN-51 inhibits STAT3 activation (phosphorylation, p-STAT3) and its downstream signaling. STAT3-IN-51 induces ROS generation, decreases Bcl-2 expression, disruptes mitochondrial function, suppresses GPX4 activity, and promotes lipid peroxidation. STAT3-IN-51 can be used for the study of colorectal carcinoma, breast adenocarcinoma, non-small cell lung cancer (NSCLC) and Cisplatin (HY-17394)-resistant pulmonary adenocarcinoma .
    STAT3-IN-51
  • HY-186158
    HOOC-OXA-COOH

    		Drug Intermediate Cancer
    HOOC-OXA-COOH is an anionic prodrug of Oxaliplatin (HY-17371). HOOC-OXA-COOH can be loaded onto nanomotors via electrostatic interaction, and undergoes cascade activation by H2S and endogenous glutathione in the tumor microenvironment to release cytotoxic Pt 2+. HOOC-OXA-COOH can be used in the research of colon cancer .
    HOOC-OXA-COOH
  • HY-182066
    Photosensitizer-9

    		PANoptosis Cancer
    Photosensitizer-9 is an iridium (III)-based photosensitizer with anti-melanoma activity. Photosensitizer-9 exhibits significant phototoxicity (IC50=0.98 μM) and an ideal phototoxicity index (PI=3.05). Under light irradiation, Photosensitizer-9 generates large amounts of intracellular •OH in an oxygen-independent manner. Photosensitizer-9 mediates photodynamic therapy under hypoxic conditions and synergistically activates PANoptosis (by upregulating cleaved Caspase-3, GSDMD-N, p-MLKL), ferroptosis (by disrupting the GSH-GPX4-LPO axis), apoptosis, pyroptosis and necroptosis in melanoma cells. Photosensitizer-9 induces immunogenic cell death by promoting the release of damage-associated molecular patterns under hypoxic conditions and increases the maturation rate of dendritic cells. Photosensitizer-9 reduces tumor volume in melanoma-bearing mice. Photosensitizer-9 is applicable to relevant studies on melanoma .
    Photosensitizer-9
  • HY-182360
    Cytisine-platinum(IV) prodrug-1

    		PERK Eukaryotic Initiation Factor (eIF) Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) STING DNA/RNA Synthesis PD-1/PD-L1 Cancer
    Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural compound Cytisine (HY-N0175) with antiproliferative activity against tumor cells. Cytisine-Platinum(IV) Prodrug-1 promotes calcium transfer across the IP3R1-GRP75-VDAC1 axis to drive mitochondrial calcium overload. Cytisine-Platinum(IV) Prodrug-1 initiates unfolded protein response via PERK, eIF2α, ATF4, and CHOP to modulate Bcl-2 and Bax, triggering apoptosis. Cytisine-Platinum(IV) Prodrug-1 induces mitochondrial dysfunction, ROS production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest. Cytisine-Platinum(IV) Prodrug-1 activates the cGAS-STING pathway, reduces PD-L1 expression, drives immunogenic cell death. Cytisine-Platinum(IV) Prodrug-1 exhibits high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding, and inhibits tumor growth in mouse models with reduced systemic toxicity. Cytisine-Platinum(IV) Prodrug-1 can be used for the research of lung cancer .
    Cytisine-platinum(IV) prodrug-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: